Equities analysts expect Theravance Biopharma, Inc. (NASDAQ:TBPH) to announce sales of $13.19 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Theravance Biopharma’s earnings, with the lowest sales estimate coming in at $10.61 million and the highest estimate coming in at $18.44 million. Theravance Biopharma reported sales of $18.26 million in the same quarter last year, which indicates a negative year-over-year growth rate of 27.8%. The business is scheduled to issue its next earnings report on Thursday, November 4th.
On average, analysts expect that Theravance Biopharma will report full year sales of $55.75 million for the current financial year, with estimates ranging from $51.56 million to $67.37 million. For the next year, analysts anticipate that the company will post sales of $134.03 million, with estimates ranging from $57.90 million to $330.71 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, August 2nd. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.22. The business had revenue of $12.91 million for the quarter, compared to analyst estimates of $15.02 million.
A number of hedge funds and other institutional investors have recently modified their holdings of TBPH. Newbridge Financial Services Group Inc. bought a new position in Theravance Biopharma in the second quarter worth about $29,000. SG Americas Securities LLC acquired a new stake in shares of Theravance Biopharma in the second quarter valued at approximately $117,000. Citigroup Inc. increased its stake in shares of Theravance Biopharma by 57.7% in the second quarter. Citigroup Inc. now owns 9,905 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 3,626 shares during the period. Handelsbanken Fonder AB acquired a new stake in shares of Theravance Biopharma in the second quarter valued at approximately $196,000. Finally, HRT Financial LP acquired a new stake in shares of Theravance Biopharma in the first quarter valued at approximately $200,000. 82.11% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Theravance Biopharma stock traded up $0.25 during trading hours on Monday, hitting $7.11. 2,797,566 shares of the company’s stock traded hands, compared to its average volume of 660,599. The stock has a 50 day simple moving average of $11.50 and a 200-day simple moving average of $16.22. The company has a market cap of $522.37 million, a PE ratio of -1.73 and a beta of 0.82. Theravance Biopharma has a twelve month low of $6.10 and a twelve month high of $22.74.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
Featured Article: What’s a Black Swan?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.